nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2015 | Image of the Month

Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma

verfasst von: Thorsten Derlin, Ulrich Baumann, Frank M. Bengel

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Excerpt

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) holds great promise in refining the restaging of prostate cancer in the context of biochemical recurrence [1‐3]. Of note, some PSMA ligands are theranostic, i.e., the same ligand can be used for diagnostic imaging and subsequent radionuclide therapy [4]. …

Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.PubMedCentralCrossRefPubMed

Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668–74.CrossRefPubMed

Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97.CrossRefPubMed

Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.CrossRefPubMed

Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.PubMed

Titel: Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma
verfasst von: Thorsten Derlin
Ulrich Baumann
Frank M. Bengel
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3161-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer

Evaluation of two novel 64Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ3

18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data

Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial

Pseudarthrosis after lumbar spinal fusion: the role of 18F-fluoride PET/CT